刊物主题:Oncology; Pharmacology/Toxicology; Cancer Research;
出版者:Springer Berlin Heidelberg
ISSN:1432-0843
卷排序:79
文摘
BackgroundThe first one-arm phase II trial aimed to evaluate and predict efficacy and safety of S-1 plus oral leucovorin (S-1/LV) as first-line chemotherapy for patients with advanced gastric cancer (AGC), using S-1 pharmacogenetic pathway approach.